Commercial Strategies
Bio-Thera has added India to its BAT2506 partnership with Intas, granting exclusive commercialization rights and expanding a global network spanning the US and Canada, as the firm builds its presence in the emerging golimumab biosimilars market.
Alvotech is shifting toward dual-source manufacturing and operational execution as it addresses FDA setbacks, expands its biosimilar pipeline and drives growth through global launches, with US approvals representing key upside to its 2026 outlook.
The approval of Wegovy HD brings a more effective version to the lower-dose version and the oral formulation, but the company has struggled to compete with obesity rival Eli Lilly.
Celltrion has added a subcutaneous formulation to its Avtozma biosimilar in the US, completing a dual-presentation strategy aimed at matching Actemra and improving uptake in a market where biosimilar penetration has so far remained limited.
Sandoz has struck a new deal with Samsung Bioepis covering up to five early-stage biosimilars, expanding an existing alliance as the Swiss-based firm ramps up investment, reorganizes its business and targets a wave of upcoming biologics loss-of-exclusivity opportunities.
The company presented updated data from the Phase III pivotal trial and plans to file for US FDA approval in the first half of the year.
With J&J’s CAR-T Carvykti also approved for second-line disease, an oncologist told Scrip multiple factors will determine who gets which therapy option.
The US FDA gave priority review to the JAK1/TYK2 inhibitor, moving the Roivant company’s potential launch date from early 2027 to September 2026.
Sandoz enjoyed good sales and profit growth in 2025, with a significant increase in free cash flow allowing the firm to continue investing in its major European biosimilars manufacturing network.
The drugmaker presented Phase III data at CROI showing the two-drug combination pill is non-inferior to existing options like Gilead’s Biktarvy, both in treated and untreated HIV patients.
Sandoz will look to muscle in on a crowded biosimilar ophthalmology market with the launch of a rival to Lucentis later this year.
The company announced updated data showing superiority for the long-acting injectable over daily pills among patients with adherence challenges.